ANTI-CANCER PROTEOLYTIC ANTIBODIES

抗癌蛋白水解抗体

• 批准号: 6779630
• 负责人: Vaughn Vasil Smider
• 金额: $ 10万
• 依托单位: INTEGRIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6779630
• 关键词: antitumor antibody; bacterial virus; bioengineering /biomedical engineering; biotechnology; combinatorial chemistry; drug design /synthesis /production; drug screening /evaluation; endopeptidases; molecular probes; neoplasm /cancer immunotherapy; neutralizing antibody; peptide library; phosphonate; polymerase chain reaction; protein binding; protein engineering; recombinant DNA; vascular endothelial growth factors

DESCRIPTION (provided by applicant): Antibody therapy is now common for several diseases. Some unique antibodies contain a protease function, with the ability to specifically degrade their target antigen. IntegriGen has cloned unique proteolytic antibody genes and will engineer them to bind and cleave therapeutically relevant target antigens. This project has three specific aims: 1) Clone and engineer libraries of proteolytic antibodies, 2) synthesize fluorophosphonate probes capable of specifically binding active proteases, and 3) screen the libraries of aim (1) against the model tumor antigen VEGF and the fluorophosphonate probe of aim (2) to discover new antigen specific proteolytic antibodies.

描述（由申请人提供）：抗体疗法现在很常见多种疾病。某些独特的抗体包含蛋白酶功能，并具有专门降解其靶抗原的能力。 Integrigen已经克隆了独特的蛋白水解抗体基因，并将它们设计它们以结合和裂解治疗相关的靶抗原。该项目具有三个特定的目的：1）蛋白水解抗体的克隆和工程师库，2）合成能够特异性结合活性蛋白酶的荧光磷酸探针，以及3）筛选目标（1）与模型肿瘤抗原VEGF的目标（1），以发现新的抗磷酸抗物的抗原蛋白质（2）新的抗原蛋白质蛋白质（2）。